Cardlytics Inc. (NASDAQ: CDLX) reported a Form 4 filing showing Chief Executive Officer Amit Gupta sold 69,833 shares of common stock on April 6, 2026. The transaction carried a weighted average price of $1.187 per share and totaled $82,891. Reported sale prices ranged between $1.135 and $1.230.
Following that disposition, Gupta is recorded as directly owning 987,387 Cardlytics shares. The company's stock was trading at $1.18 at the time of reporting, a level that InvestingPro data indicates is 26% higher than a week earlier but 56% below its price six months ago.
The Form 4 filing specifies the sale was undertaken exclusively to satisfy tax obligations stemming from Restricted Stock Units that vested on April 1, 2026.
Recent corporate results and strategic changes
Cardlytics released results for the fourth quarter of fiscal 2025 that showed stronger-than-expected top-line performance alongside continued losses per share. Revenue for the quarter was $56.1 million, compared with analysts' consensus of $55.17 million, representing a 1.69% positive surprise. Reported earnings per share were -$0.28, which matched analysts' expectations.
Separately, Cardlytics completed the sale of its Bridg platform assets to PAR Technology Corporation. As consideration, Cardlytics received 1,810,222 shares of PAR Technology common stock.
Analysts have adjusted their outlooks in light of recent developments. Evercore ISI lowered its price target for Cardlytics from $2 to $1 while keeping an In Line rating, citing the termination of the relationship with Bank of America and ongoing content restrictions at Chase. BofA Securities likewise trimmed its price target, taking it to $0.90 from $1.50 and maintaining an Underperform rating, specifically pointing to concerns tied to developments with major financial partners.
Context and market reaction
The insider sale was structured as a tax-withholding transaction associated with RSU vesting. At the same time, Cardlytics' market valuation and analyst reception have been affected by partner-related dynamics and operational shifts disclosed in recent company communications.
Investors and market participants monitoring Cardlytics will likely weigh the company's modest revenue beat against persistent EPS losses and evolving relationships with major financial institutions - factors that have prompted some firms to lower price targets while leaving ratings unchanged.